Global Transcranial Magnetic Stimulators Market Size By Type (Single Pulse Transcranial Magnetic Stimulators, Repetitive Transcranial Magnetic Stimulators ), By Application, By End-User, By Geographic Scope And Forecast

Transcranial Magnetic Stimulators Market Size And Forecast

Transcranial Magnetic Stimulators Market size was valued at USD 1.13 Billion in 2024 and is projected to reach USD 2.16 Billion by 2032, growing at a CAGR of 8.45% from 2026 to 2032.

Transcranial Magnetic Stimulation (TMS) is a non-invasive medical procedure that uses electromagnetic fields to stimulate nerve cells in the brain. This technique involves placing a magnetic coil against the scalp, which generates a magnetic field that induces electric currents in specific brain areas. TMS is primarily used to modulate neuronal activity and has been widely researched for its therapeutic potential in various neurological and psychiatric conditions.

TMS has been most prominently applied in the treatment of major depressive disorder, especially in patients who do not respond to traditional therapies like medication and psychotherapy.

It is also being explored for treating other conditions such as anxiety disorders, post-traumatic stress disorder (PTSD), and chronic pain. The procedure is typically performed in an outpatient setting, with patients receiving multiple sessions over several weeks.

Additionally, TMS is used in research to study brain function and connectivity, helping to advance our understanding of neurological disorders.

The future scope of TMS is promising, with ongoing research aimed at expanding its therapeutic applications and improving its efficacy. Advances in technology may lead to more precise targeting of brain regions and individualized treatment protocols based on specific patient needs.

Transcranial Magnetic Stimulators Market is estimated to grow at a CAGR of 8.45% & reach US$ 2.16 Bn by the end of 2032

Global Transcranial Magnetic Stimulators Market Dynamics

The key market dynamics that are shaping the global transcranial magnetic stimulators market include:

Key Market Drivers

Increasing Prevalence of Depression and Mental Disorders: The rising number of individuals diagnosed with major depressive disorder and other mental health conditions drives the demand for effective treatments like TMS, particularly for patients resistant to conventional therapies. According to the World Health Organization (WHO), as of 2022, approximately 280 million people worldwide were living with depression. In the United States, the National Institute of Mental Health (NIMH) reported that in 2020, an estimated 21 million adults had at least one major depressive episode, representing 8.4% of all U.S. adults.

Technological Advancements: Continuous innovations in TMS technology, such as more precise targeting of brain areas and the development of portable devices, enhance treatment outcomes and expand the scope of TMS applications, fueling market growth. BrainsWay, another major player, launched its Deep TMS H7 Coil for treating adults with anxious depression in January 2024, expanding the applications of their technology.

Growing Awareness and Acceptance: Increasing awareness among healthcare providers and patients about the benefits and efficacy of TMS as a non-invasive treatment option leads to higher adoption rates, contributing to market expansion. The American Psychiatric Association (APA) updated its treatment guidelines for major depressive disorder in 2022, recommending TMS as a second-line treatment for patients who have not responded to at least one antidepressant medication.

Favorable Regulatory Environment: Supportive regulatory policies and approvals from health authorities, such as the FDA in the United States, facilitate the commercialization and adoption of TMS devices, encouraging market growth. The European Medicines Agency (EMA) issued updated guidelines for the clinical investigation of medical devices for TMS in 2024, streamlining the approval process for new TMS devices in the European market.

Key Challenges:

Limited Insurance Coverage: Insufficient reimbursement policies and limited insurance coverage for TMS treatments hinder patient access and uptake, posing a challenge for market growth.

Lack of Awareness and Training: A deficit in awareness among both patients and healthcare professionals, coupled with a need for specialized training to administer TMS, restricts its widespread implementation and acceptance.

Mixed Clinical Outcomes: Variability in treatment outcomes and the need for more extensive, long-term clinical trials to establish consistent efficacy across different patient populations can affect confidence in TMS as a reliable therapy.

Regulatory and Approval Hurdles: Stringent regulatory requirements and the lengthy approval process for new TMS devices and applications can delay market entry and innovation, challenging market expansion.

Key Trends

Personalized TMS Treatments: Advances in neuroimaging and AI are enabling the development of personalized TMS protocols tailored to individual brain patterns, improving treatment efficacy and patient outcomes. According to a study published in Nature Neuroscience in September 2024, personalized TMS protocols based on individual brain connectivity patterns showed a 40% improvement in treatment outcomes for major depressive disorder compared to standard protocols.

Integration with Digital Health Platforms: The incorporation of TMS therapy into digital health ecosystems, including telemedicine and remote monitoring, enhances patient accessibility and allows for more comprehensive treatment management. A report by the American Telemedicine Association (ATA) in December 2024 indicated that the integration of TMS with telemedicine services increased by 65% in 2024 compared to the previous year.

Expansion into New Therapeutic Areas: Ongoing research and clinical trials are exploring the use of TMS for a wider range of conditions, such as Alzheimer's disease, stroke rehabilitation, and addiction, broadening the market's scope and potential applications. The Alzheimer's Association reported in February 2024 that three large-scale clinical trials evaluating TMS for Alzheimer's disease were in phase III, with preliminary results showing promising cognitive improvements in mild to moderate cases.

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Transcranial Magnetic Stimulators Market Regional Analysis

Here is a more detailed regional analysis of the global transcranial magnetic stimulators market:

North America

North America is dominating the transcranial magnetic stimulators (TMS) market owing to the high prevalence of depression and other mental health disorders, advanced healthcare infrastructure, and strong regulatory support. The U.S. TMS market was valued at USD 400 Million in 2024 and was projected to grow at a CAGR of 8.5% from 2024 to 2032, according to data from the Medical Device Manufacturers Association (MDMA) released in March 2024.

The United States, in particular, has a large number of TMS service providers and ongoing clinical research, which contribute to market growth. The region benefits from favorable reimbursement policies and the widespread adoption of new medical technologies. The Anxiety and Depression Association of America (ADAA) stated in February 2024 that approximately 40% of patients with major depressive disorder in the U.S. were considered treatment-resistant, making them potential candidates for TMS therapy.

Asia Pacific

The Asia-Pacific region is experiencing rapid growth in the TMS market due to rising healthcare investments, expanding mental health awareness, and increasing prevalence of neurological disorders. According to a report by the Asia Pacific Medical Technology Association (APACMed) released in February 2024, the TMS market in the Asia-Pacific region was valued at USD 180 Million in 2024 and was projected to grow at a CAGR of 12.5% from 2024 to 2032.

Countries such as China, Japan, and South Korea are at the forefront of this growth, with improving healthcare infrastructure and growing adoption of advanced medical treatments. The China Medical Device Industry Association reported in December 2024 that the Chinese TMS market grew by 18% in 2024 compared to the previous year.

The region's large population base and increasing disposable income also contribute to market expansion. The Japanese Ministry of Health, Labour and Welfare announced in March 2024 a 15% increase in budget allocation for mental health services, including support for TMS treatment centers.

Global Transcranial Magnetic Stimulators Market: Segmentation Analysis

The Global Transcranial Magnetic Stimulators Market is Segmented on the basis of Type, Application, End-User, and Geography.

Transcranial Magnetic Stimulators Market Segmentation Analysis

Transcranial Magnetic Stimulators Market, By Type

• Single Pulse Transcranial Magnetic Stimulators
• Repetitive Transcranial Magnetic Stimulators (rTMS)
• Theta Burst Transcranial Magnetic Stimulators (TBS)

Based on Type, the Global Transcranial Magnetic Stimulators Market is bifurcated into Single Pulse Transcranial Magnetic Stimulators, Repetitive Transcranial Magnetic Stimulators (rTMS), and Theta Burst Transcranial Magnetic Stimulators (TBS). Repetitive transcranial magnetic stimulators (rTMS) currently dominate the transcranial magnetic stimulators market due to their widespread use in treating major depressive disorder and other psychiatric conditions. rTMS is well-established, with extensive clinical evidence supporting its efficacy, making it the preferred choice for many practitioners. Theta burst transcranial magnetic stimulators (TBS) are rapidly growing in popularity as the second-leading segment, driven by their shorter treatment times and emerging research indicating comparable or superior effectiveness to traditional rTMS, thus appealing to both patients and healthcare providers seeking efficient treatment options.

Transcranial Magnetic Stimulators Market, By Application

• Neuropsychiatry
• Neurology
• Research and Development
• Diagnostic Imaging

Based on Application, the Global Transcranial Magnetic Stimulators Market is bifurcated into Neuropsychiatry, Neurology, Research and Development, and Diagnostic Imaging. Neuropsychiatry is the dominating segment in the transcranial magnetic stimulators market, primarily due to the widespread adoption of TMS for treating major depressive disorder, treatment-resistant depression, and other psychiatric conditions. This application has gained significant traction due to strong clinical evidence and growing acceptance in the medical community. Neurology is the second rapidly growing segment, fueled by increasing research and clinical trials exploring the use of TMS for various neurological conditions such as stroke rehabilitation, Parkinson's disease, and chronic pain, expanding the potential therapeutic applications of TMS beyond mental health.

Transcranial Magnetic Stimulators Market, By End-User

• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostic Imaging Centers

Based on End-User, the Global Transcranial Magnetic Stimulators Market is bifurcated into Hospitals, Specialty Clinics, Research Institutes, and Diagnostic Imaging Centers. Hospitals dominate the transcranial magnetic stimulators market as the primary end-users, leveraging their advanced infrastructure, broad patient base, and comprehensive medical services to provide TMS treatments, particularly for psychiatric and neurological disorders. Specialty Clinics are the second rapidly growing segment, driven by their focused expertise, personalized care, and increasing adoption of TMS for mental health treatments, making them a preferred choice for patients seeking specialized and accessible treatment options.

Transcranial Magnetic Stimulators Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Transcranial Magnetic Stimulators Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the transcranial magnetic stimulators market due to its advanced healthcare infrastructure, high prevalence of mental health disorders, and strong regulatory support, particularly in the United States. Europe follows as the second rapidly growing segment, driven by increasing mental health awareness, supportive healthcare policies, and significant investments in mental health services, with key countries like Germany, the United Kingdom, and France leading the adoption of TMS technology.

Key Players

The "Global Transcranial Magnetic Stimulators Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are BrainsWay, Magstim, Nexstim, Salience, MagVenture A/S, Neuronetics, Axilum Robotics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Transcranial Magnetic Stimulators Market Key Developments

• In March 2024, Neuronetics, Inc. received FDA clearance for its NeuroStar Advanced Therapy system, incorporating new software algorithms aimed at improving treatment outcomes for depression. This clearance is expected to boost the company's market share and drive adoption rates.
• In June 2024, BrainsWay Ltd. announced the successful completion of a Phase III clinical trial for its Deep TMS (dTMS) device targeting obsessive-compulsive disorder (OCD). This development is anticipated to broaden the application of dTMS and increase market penetration.
• In August 2024, Ybrain Inc. launched a new portable TMS device designed for home use. This innovation aims to make TMS therapy more accessible to patients and reduce the need for frequent clinic visits.